Back to Search Start Over

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

Authors :
Salles, Gilles
Schuster, Stephen J.
Dreyling, Martin
Fischer, Luca
Kuruvilla, John
Patten, Piers E. M.
von Tresckow, Bastian
Smith, Sonali M.
Jiménez-Ubieto, Ana
Davis, Keith L.
Anjos, Carla
Chu, Jufen
Zhang, Jie
Lobetti Bodoni, Chiara
Thieblemont, Catherine
Fowler, Nathan H.
Dickinson, Michael
Martínez-López, Joaquin
Wang, Yucai
Link, Brian K.
Source :
Blood Advances; November 2022, Vol. 6 Issue: 22 p5835-5843, 9p
Publication Year :
2022

Abstract

•Our study contextualizes the single-arm ELARA trial by providing historical control data from clinically similar patients on usual care.•Tisagenlecleucel was shown to have superior efficacy than usual care in patients with multiply relapsed or refractory follicular lymphoma.

Details

Language :
English
ISSN :
24739529 and 24739537
Volume :
6
Issue :
22
Database :
Supplemental Index
Journal :
Blood Advances
Publication Type :
Periodical
Accession number :
ejs61827661
Full Text :
https://doi.org/10.1182/bloodadvances.2022008150